Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Cash per Share : $0.18 (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Parnell Pharmaceuticals Holdings's Cash per Share for the quarter that ended in Dec. 2018 was $0.18.

Parnell Pharmaceuticals Holdings Cash per Share Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Cash per Share Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Cash per Share

Get a 7-Day Free Trial

1.47

0.31

0.29

0.10

0.18

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Cash per Share	Get a 7-Day Free Trial			1.47	0.31	0.29	0.10	0.18

Parnell Pharmaceuticals Holdings Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Parnell Pharmaceuticals Holdings's Cash per Share for the fiscal year that ended in Dec. 2018 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	3.155	/	18.03
	=	0.18

Parnell Pharmaceuticals Holdings's Cash per Share for the quarter that ended in Dec. 2018 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	3.155	/	18.03
	=	0.18

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Parnell Pharmaceuticals Holdings Cash per Share Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.